CorMedix Company Insiders

CRMD Stock  USD 10.49  0.02  0.19%   
CorMedix employs about 82 people. The company is managed by 8 executives with a total tenure of roughly 192 years, averaging almost 24.0 years of service per executive, having 10.25 employees per reported executive. Evaluation of CorMedix's management performance can provide insight into the firm performance.

Insider Sentiment 50

 Impartial

 
Selling
 
Buying

Latest Trades

2024-11-14Elizabeth HurlburtDisposed 140027 @ 11.18View
2024-10-31Erin MistryAcquired 1500 @ 9.99View
Monitoring CorMedix's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CorMedix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
For information on how to trade CorMedix Stock refer to our How to Trade CorMedix Stock guide.

CorMedix's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CorMedix's future performance. Based on our forecasts, it is anticipated that CorMedix will maintain a workforce of about 80 employees by April 2025.
 
Credit Downgrade
 
Yuan Drop
 
Covid

CorMedix Management Team Effectiveness

The company has return on total asset (ROA) of (0.3769) % which means that it has lost $0.3769 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6504) %, meaning that it created substantial loss on money invested by shareholders. CorMedix's management efficiency ratios could be used to measure how well CorMedix manages its routine affairs as well as how well it operates its assets and liabilities. As of March 18, 2025, Return On Tangible Assets is expected to decline to -0.53. In addition to that, Return On Capital Employed is expected to decline to -0.84. At present, CorMedix's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 3.2 M, whereas Return On Tangible Assets are forecasted to decline to (0.53).
The current year's Common Stock Shares Outstanding is expected to grow to about 61.5 M, whereas Net Loss is forecasted to decline to (28.1 M).

CorMedix Workforce Comparison

CorMedix is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,844. CorMedix holds roughly 82.0 in number of employees claiming about 2.88% of equities under Health Care industry.

CorMedix Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CorMedix insiders, such as employees or executives, is commonly permitted as long as it does not rely on CorMedix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CorMedix insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
2.25
9
4
 863,561 
 27,989 
2023-12-01
6.0
6
1
 272,000 
 15,000 
2023-06-01
5.5
11
2
 101,200 
 37,443 
2023-03-01
11.0
11
1
 970,000 
 0.00 
2021-12-01
1.5
6
4
 138,000 
 35,000 
2021-06-01
3.0
3
1
 282,500 
 8,000 
2018-12-01
2.7143
19
7
 2,636,303 
 3,000,529 
2018-09-01
0.5
1
2
 13,636 
 2,000,000 
2018-03-01
14.5
29
2
 1,132,749 
 25,357 
2017-12-01
11.0
11
1
 611,566 
 18,028 
2017-09-01
3.3333
10
3
 662,040 
 2,000,000 
2017-06-01
14.0
14
1
 458,999 
 0.00 
2017-03-01
3.8333
23
6
 1,107,560 
 246,057 
2016-12-01
4.0
12
3
 3,147,694 
 40,000 
2016-09-01
4.0
8
2
 214,105 
 150,000 
2016-06-01
1.0303
34
33
 547,166 
 451,106 
2016-03-01
11.0
11
1
 568,556 
 30,000 
2015-09-01
4.0
4
1
 70,327 
 0.00 
2015-06-01
1.2308
16
13
 189,457 
 238,581 
2015-03-01
4.3333
13
3
 434,858 
 297,500 
2014-12-01
11.0
11
1
 99,364 
 5,000 
2014-09-01
6.0
6
1
 119,493 
 0.00 
2014-03-01
2.6
26
10
 1,832,500 
 988,796 
2013-12-01
1.3333
4
3
 89,428 
 114,285 
2013-09-01
2.5
10
4
 575,171 
 528,696 
2013-03-01
4.5
9
2
 1,780,000 
 50,000 
2011-12-01
4.0
8
2
 86,500 
 4,884 
2011-09-01
0.5
1
2
 30,000 
 19,536 
2010-03-01
1.2222
22
18
 3,313,330 
 1,398,766 

CorMedix Notable Stakeholders

A CorMedix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CorMedix often face trade-offs trying to please all of them. CorMedix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CorMedix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Matthew MDExecutive CFOProfile
Kaufman EsqChief EVPProfile
Joseph MBACEO DirectorProfile
Donna UcciSenior QualityProfile
Tushar MukherjeeSenior OperationsProfile
Phoebe EsqGen EVPProfile
Elizabeth BAExecutive AffairsProfile
Erin MistryExecutive OfficerProfile

About CorMedix Management Performance

The success or failure of an entity such as CorMedix often depends on how effective the management is. CorMedix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CorMedix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CorMedix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.51)(0.53)
Return On Capital Employed(0.80)(0.84)
Return On Assets(0.51)(0.53)
Return On Equity(0.76)(0.72)
Please note, the presentation of CorMedix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CorMedix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CorMedix's management manipulating its earnings.

CorMedix Workforce Analysis

Traditionally, organizations such as CorMedix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CorMedix within its industry.

CorMedix Manpower Efficiency

Return on CorMedix Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee565.1K
Net Loss Per Executive5.8M
Working Capital Per Employee829.9K
Working Capital Per Executive8.5M

Complementary Tools for CorMedix Stock analysis

When running CorMedix's price analysis, check to measure CorMedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CorMedix is operating at the current time. Most of CorMedix's value examination focuses on studying past and present price action to predict the probability of CorMedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CorMedix's price. Additionally, you may evaluate how the addition of CorMedix to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio